Modality
Peptide
MOA
IL-13i
Target
B7-H3
Pathway
Fibrosis
Hemophilia A
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
~Apr 2017
→ ~Jul 2018
Phase 3
Oct 2018
→ Sep 2031
Phase 3Current
NCT03124958
457 pts·Hemophilia A
2023-02→2031-09·Terminated
NCT06586191
2,309 pts·Hemophilia A
2018-10→2026-03·Not yet recruiting
2,766 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-256d agoPh3 Readout· Hemophilia A
2031-09-055.4y awayPh3 Readout· Hemophilia A
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
P3
Termina…
Catalysts
Ph3 Readout
2026-03-25 · 6d ago
Hemophilia A
Ph3 Readout
2031-09-05 · 5.4y away
Hemophilia A
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03124958 | Phase 3 | Hemophilia A | Terminated | 457 | EFS |
| NCT06586191 | Phase 3 | Hemophilia A | Not yet recr... | 2309 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 |